Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Pituitary Disorders
•
General Endocrinology
When do you recommend using L-arginine stimulated copeptin testing to evaluate for central diabetes insipidus (AVP-deficiency)?
Related Questions
Does growth hormone (GH) replacement therapy reduce the risk of fractures in patients with GH deficiency?
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
What is your approach to differentiating diabetes insipidus from primary polydipsia in the outpatient setting?
Would you order a fibroscan to screen for MASLD in patients with insulin resistance but normal LFTs?
Do you interpret failure to develop hypernatremia with prolonged water deprivation (such as for 12 hours) as evidence against diabetes insipidus even if the urine osmolality is just below normal?
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
What is the typical timeline for remission of autoimmune hypoglycemia?
When and how do you taper off cabergoline therapy for treatment of microprolactinoma?
For patients with central hypothyroidism and a clear etiology (such as recent head irradiation), do you recommend brain imaging prior to starting thyroid hormone replacement therapy?
Is inositol just as effective as metformin in treating insulin resistance associated with PCOS?
